This 83% relative difference indicates that tirzepatide is often being used early in the treatment pathway, potentially reducing reliance on first-time initiation of device-based therapy
Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.
In overweight or obese patients with no history of T2DM, tirzepatide achieved a significant approximately 6 mmHg SBP reduction in the SURMOUNT-1 trial [38]
This holistic improvement in both physiological health and patient-reported outcomes underscores the transformative potential of these therapies in the comprehensive management of OSA and obesity
GLP-1 receptor agonists (GLP-1RAs), including clinically approved agents such as semaglutide, liraglutide, and dulaglutide, are widely used for glycemic control in patients with type 2 diabetes and have demonstrated cardiovascular benefits ( 2 Mechanistic insights into GLP-1RA actions in atherosclerosis GLP-1RA influences multiple stages of atherosclerosis, including inflammation, endothelial dysfunction, and lipid metabolism, through interconnected molecular pathways
Cardiovascular and Metabolic Effects Injectable semaglutide currently has stronger long-term cardiovascular outcome data
